Newland Pharmaceutical Co., Ltd. (301277.SZ)
- Previous Close
12.50 - Open
12.96 - Bid 11.82 x --
- Ask 11.83 x --
- Day's Range
11.74 - 12.37 - 52 Week Range
8.27 - 14.23 - Volume
22,126,953 - Avg. Volume
13,839,860 - Market Cap (intraday)
4.916B - Beta (5Y Monthly) --
- PE Ratio (TTM)
26.84 - EPS (TTM)
0.44 - Earnings Date --
- Forward Dividend & Yield 0.29 (2.29%)
- Ex-Dividend Date Apr 16, 2025
- 1y Target Est
--
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. The company offers pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. It also provides APIs, such as ropivacaine hydrochloride, naphazoline hydrochloride, moxifloxacin hydrochloride, lidocaine hydrochloride, vildagliptin, tadalafil, chlorpheniramine maleate, clopidogrel bisulfate, lidocaine, gatifloxacin, febuxostat, esomeprazole sodium, and esomeprazole magnesium. The company was formerly known as Henan Newland Pharmaceutical Co., Ltd. and changed its name to Newland Pharmaceutical Co., Ltd. in June 2023. Newland Pharmaceutical Co., Ltd. was founded in 2005 and is based in Changge City, China.
www.newlandpharma.com1,042
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 301277.SZ
View MorePerformance Overview: 301277.SZ
Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 301277.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 301277.SZ
View MoreValuation Measures
Market Cap
4.90B
Enterprise Value
4.12B
Trailing P/E
28.23
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.45
Price/Book (mrq)
3.06
Enterprise Value/Revenue
5.41
Enterprise Value/EBITDA
20.40
Financial Highlights
Profitability and Income Statement
Profit Margin
22.88%
Return on Assets (ttm)
6.55%
Return on Equity (ttm)
11.21%
Revenue (ttm)
761.64M
Net Income Avi to Common (ttm)
174.28M
Diluted EPS (ttm)
0.44
Balance Sheet and Cash Flow
Total Cash (mrq)
787.53M
Total Debt/Equity (mrq)
0.48%
Levered Free Cash Flow (ttm)
46.47M